ClinicalTrials.gg
CompletedNCT01579084Updated Nov 18, 2019Results posted

Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea

A Phase 1 interventional study of AGN-199201 Formulation A and AGN-199201 Formulation B in Rosacea and Erythema, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.

Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 145 studies in Rosacea with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Rosacea · United States.

Enrollment
73rd of 137
64 · median 78
Started
2012
with 10 others
Phase 1
18 of 145
none open now
Registered
42nd of 145
by date
Lead sponsor
7 of 145
Allergan

Among the 145 studies in Rosacea with a site in United States, this one is the 73rd largest by enrollment of the 137 interventional ones that give a count, is one of 11 that started in 2012, is one of 18 in phase 1, and was the 42nd registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

8 of the 145 studies in Rosacea with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 145 studies in Rosacea with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.

03

Conditions studied

  • Rosacea
  • Erythema

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • facial erythema associated with rosacea on both sides of the face

Exclusion criteria

Exclusion Criteria:

  • Laser light-source or other energy based therapy in the last 6 months
  • Excessive hair around the treatment area
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    AGN-199201 Formulation A and B

    AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily.

    Drug: AGN-199201 Formulation A · Drug: AGN-199201 Formulation B

  • Experimental
    AGN-199201 Formulation B and C

    AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily.

    Drug: AGN-199201 Formulation B · Drug: AGN-199201 Formulation C

  • Experimental
    AGN-199201 Formulation C and A

    AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily.

    Drug: AGN-199201 Formulation A · Drug: AGN-199201 Formulation C

  • Other
    AGN-199201 Formulation A and Vehicle

    AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.

    Drug: AGN-199201 Formulation A · Drug: AGN-199201 Vehicle

  • Other
    AGN-199201 Formulation B and Vehicle

    AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.

    Drug: AGN-199201 Formulation B · Drug: AGN-199201 Vehicle

  • Other
    AGN-199201 Formulation C and Vehicle

    AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily.

    Drug: AGN-199201 Formulation C · Drug: AGN-199201 Vehicle

  • Experimental
    AGN-199201 Formulation A

    AGN-199201 Formulation A applied to both sides of the face twice daily.

    Drug: AGN-199201 Formulation A

  • Experimental
    AGN-199201 Formulation B

    AGN-199201 Formulation B applied to both sides of the face twice daily.

    Drug: AGN-199201 Formulation B

  • Experimental
    AGN-199201 Formulation C

    AGN-199201 Formulation C applied to both sides of the face twice daily.

    Drug: AGN-199201 Formulation C

  • Placebo comparator
    AGN-199201 Vehicle

    AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.

    Drug: AGN-199201 Vehicle

Interventions

  • AGN-199201 Formulation A applied to the face as per protocol twice daily.

  • AGN-199201 Formulation B applied to the face as per protocol twice daily.

  • AGN-199201 Formulation C applied to the face as per protocol twice daily.

  • DrugAGN-199201 Vehicle

    AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1

    The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

    Time frame: Baseline, Day 1-hour 6

  2. Percentage of Responders With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 5

    The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

    Time frame: Baseline, Day 5-hour 6

Secondary outcomes

  1. Percentage of Responders With at Least a 2-Grade Decrease From Baseline on CEA

    The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score at Day 1 and Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness.

    Time frame: Baseline, Day 1-hour 6, Day 5-hour 6

  2. Percentage of Responders With at Least a 2-Grade Decrease From Baseline on SSA

    The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1 and Day 5. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

    Time frame: Baseline, Day1-hour 6, Day 5-hour 6

07

Results

Posted Nov 15, 2013

Participant flow

Participant flow — Overall Study
MilestoneAGN-199201 Formulation A and BAGN-199201 Formulation B and CAGN-199201 Formulation C and AAGN-199201 Formulation A and VehicleAGN-199201 Formulation B and VehicleAGN-199201 Formulation C and VehicleAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 Vehicle
Started8888884444
Completed8888884444
Not completed0000000000

Outcome measures

PrimaryPercentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1

The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

Time frame:
Baseline, Day 1-hour 6
Reported as:
Number · Percentage of responders
Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 1
Percentage of respondersAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 Vehicle
Percentage of Responders With at Least a 2-Grade Decrease From Baseline in Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 115.621.928.10.0
SecondaryPercentage of Responders With at Least a 2-Grade Decrease From Baseline on CEA

The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score at Day 1 and Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness.

Time frame:
Baseline, Day 1-hour 6, Day 5-hour 6
Reported as:
Number · Percentage of responders
Percentage of Responders With at Least a 2-Grade Decrease From Baseline on CEA
Percentage of respondersAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 Vehicle
Day 1-hour 634.434.440.60.0
Day 5-hour 6 (Facial Sides n=32,31,31,32)15.66.56.56.3
SecondaryPercentage of Responders With at Least a 2-Grade Decrease From Baseline on SSA

The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 1 and Day 5. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

Time frame:
Baseline, Day1-hour 6, Day 5-hour 6
Reported as:
Number · Percentage of responders
Percentage of Responders With at Least a 2-Grade Decrease From Baseline on SSA
Percentage of respondersAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 Vehicle
Day1-hour 631.346.956.33.1
Day 5-hour 6 (Facial Sides n=32,31,31,32)34.441.958.128.1
PrimaryPercentage of Responders With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 5

The percentage of responders was determined by facial sides with at least a 2-grade decrease from Baseline (Improvement) in the CEA score and at least a 2-grade decrease from Baseline (Improvement) in the SSA score at Day 5. The investigator evaluated the severity of the participant's erythema (redness of the skin) as measured by the CEA using a 5-point scale where 0=clear skin with no signs of erythema; 1=almost clear of erythema, slight redness; 2=mild erythema, definite redness; 3=moderate erythema, marked redness and 4=severe erythema, fiery redness. The participant assessed the severity of their erythema as measured by the SSA using a 5-point scale where 0=clear of unwanted redness; 1=nearly clear of unwanted redness; 2=somewhat more redness than I prefer; 3=more redness than I prefer and 4=completely unacceptable redness.

Time frame:
Baseline, Day 5-hour 6
Reported as:
Number · Percentage of responders
Percentage of Responders With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 5
Percentage of respondersAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 Vehicle
Percentage of Responders With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject's Self Assessment (SSA) at Day 56.36.56.53.1

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AGN-199201 Formulation A and B—0/8 (0%)3/8 (37.5%)
AGN-199201 Formulation B and C—0/8 (0%)5/8 (62.5%)
AGN-199201 Formulation C and A—0/8 (0%)3/8 (37.5%)
AGN-199201 Formulation A and Vehicle—0/8 (0%)6/8 (75%)
AGN-199201 Formulation B and Vehicle—0/8 (0%)6/8 (75%)
AGN-199201 Formulation C and Vehicle—0/8 (0%)4/8 (50%)
AGN-199201 Formulation A—0/4 (0%)3/4 (75%)
AGN-199201 Formulation B—0/4 (0%)3/4 (75%)
AGN-199201 Formulation C—0/4 (0%)3/4 (75%)
AGN-199201 Vehicle—0/4 (0%)2/4 (50%)
Most frequent other events
Showing 10 of 34
Most frequent other events
EventAGN-199201 Formulation A and BAGN-199201 Formulation B and CAGN-199201 Formulation C and AAGN-199201 Formulation A and VehicleAGN-199201 Formulation B and VehicleAGN-199201 Formulation C and VehicleAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 Vehicle
Application site painGeneral disorders1/81/80/81/80/82/80/40/42/40/4
Application site papulesGeneral disorders1/83/80/82/82/80/82/41/42/40/4
Application site paraesthesiaGeneral disorders1/82/82/82/80/81/80/42/40/40/4
Application site pustulesInfections and infestations0/80/80/81/81/80/81/41/42/40/4
HeadacheNervous system disorders0/82/80/81/83/83/81/40/40/40/4
NauseaGastrointestinal disorders0/80/81/80/80/80/80/41/40/40/4
Application site erythemaGeneral disorders0/81/80/80/81/81/80/41/40/40/4
Application site noduleGeneral disorders0/80/80/80/80/80/80/40/40/41/4
Application site pruritusGeneral disorders1/81/80/80/81/81/80/40/41/40/4
Application site rashGeneral disorders0/80/80/80/80/80/80/41/40/40/4

Baseline characteristics

Age, Customized
Age, Customized(Participants)AGN-199201 Formulation A and BAGN-199201 Formulation B and CAGN-199201 Formulation C and AAGN-199201 Formulation A and VehicleAGN-199201 Formulation B and VehicleAGN-199201 Formulation C and VehicleAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 VehicleTotal
< 45 years111401011010
45 to 65 years766487332450
> 65 years01100010104
Sex: Female, Male
Sex: Female, Male(Participants)AGN-199201 Formulation A and BAGN-199201 Formulation B and CAGN-199201 Formulation C and AAGN-199201 Formulation A and VehicleAGN-199201 Formulation B and VehicleAGN-199201 Formulation C and VehicleAGN-199201 Formulation AAGN-199201 Formulation BAGN-199201 Formulation CAGN-199201 VehicleTotal
Female586757242349
Male302131202115
08

Study locations

1 site
  • Austin, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2012
First posted
Apr 17, 2012
Start
Apr 2012
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Nov 15, 2013
Last update
Nov 18, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01579084
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Apr 17, 2012
Start date
Apr 2012
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Nov 15, 2013
Last update
Nov 18, 2019

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxymetazoline

Start the discussion